Sugi Predict

Sugi Predict / Compounds / SCHEMBL1424697

SCHEMBL1424697

SCHEMBL1424697

Cc1c(F)ccc([N+](=O)[O-])c1C

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.56
▸ TSHR P16473 8/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ ATM Q13315 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.48
▸ HIF1A Q16665 2/20 0.48
▸ CYP3A4 P08684 2/20 0.47
▸ MAPT P10636 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ VCAM1 P19320 1/20 0.46
▸ CASP6 P55212 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.43
▸ MAPK1 P28482 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ TP53 P04637 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29788829 1.00 TDP1 (0.56) TDP1TSHRSMN1; SMN2ATMALDH1A1
SCHEMBL29888274 0.87 TDP1 (0.50) TDP1TSHRSMN1; SMN2ATMALDH1A1
SCHEMBL574038 0.87 TDP1 (0.50) TDP1TSHRSMN1; SMN2ATMALDH1A1
SCHEMBL9719281 0.86 TDP1 (0.71) TDP1TSHRSMN1; SMN2ATMALDH1A1
SCHEMBL30503599 0.86 TDP1 (0.71) TDP1TSHRSMN1; SMN2ATMALDH1A1
SCHEMBL29902915 0.85 TDP1 (0.54) TDP1TSHRSMN1; SMN2ATMALDH1A1
SCHEMBL2481319 0.85 TDP1 (0.54) TDP1TSHRSMN1; SMN2ATMALDH1A1
SCHEMBL397110 0.83 TDP1 (0.52) TDP1TSHRSMN1; SMN2ATMALDH1A1
SCHEMBL1636077 0.82 TDP1 (0.60) TDP1TSHRSMN1; SMN2ATMALDH1A1
SCHEMBL1193417 0.82 TDP1 (0.46) TDP1TSHRSMN1; SMN2ATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695256-A2 ERBB2 INHIBITORS Cogent Biosciences, Inc. (US) 2026-02-18 — — EP disclosed
EP-3590516-B1 ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2025-09-03 — — EP disclosed
US-20250129078-A1 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. 2025-04-24 — — US disclosed
WO-2024215809-A2 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. (US) 2024-10-17 — — WO disclosed
EP-4126855-B1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2024-04-24 — — EP disclosed
US-20240083853-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, INC. 2024-03-14 — — US disclosed
CN-116600801-A HSD17B13 inhibitors and uses thereof FL2022-001公司 2023-08-15 — — CN disclosed
EP-4221701-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, Inc. (US) 2023-08-09 — — EP disclosed
CN-114907339-B 4- (4-aminophenoxy) pyridin-2-amine derivatives and use thereof 成都奥睿药业有限公司 2023-07-14 — — CN disclosed
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-07-11 — — US disclosed
WO-2009037308-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2009-03-26 — — WO disclosed
US-20080058383-A1 Androgen Receptor Modulators KARO BIO AB (SE) 2008-03-06 — — US disclosed
US-20080058383-A1 Androgen Receptor Modulators KARO BIO AB (SE) 2008-03-06 — — US disclosed
US-20080058383-A1 Androgen Receptor Modulators KARO BIO AB (SE) 2008-03-06 — — US disclosed
EP-1625129-B1 HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT BAYER HEALTHCARE AG (DE) 2008-03-05 — — EP disclosed
US-20070185121-A1 Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents BAYER HEALTHCARE AG (DE) 2007-08-09 — — US disclosed
EP-1685090-A1 ANDROGEN RECEPTOR MODULATORS KARO BIO AB (SE) 2006-08-02 — — EP disclosed
EP-1625129-A1 HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT Bayer HealthCare AG (DE) 2006-02-15 — — EP disclosed
WO-2005042464-A1 ANDROGEN RECEPTOR MODULATORS KARO BIO AB (SE) 2005-05-12 — — WO disclosed
WO-2004099212-A1 HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT BAYER HEALTHCARE AG (DE) 2004-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound ZYX, DPYD, ZFX TDP1 1109/4885TSHR 2852/4885SMN1; SMN2 2489/4885
US-20240083853-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B11, HSD17B1 TDP1 1184/4885TSHR 4218/4885SMN1; SMN2 3176/4885
US-20070185121-A1 Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents TYMP, RPL35, EIF2AK2 TDP1 461/4885TSHR 4876/4885SMN1; SMN2 2258/4885
US-20250129078-A1 ERBB2 INHIBITORS ERBB2, ERBB3, EGFR TDP1 2988/4885TSHR 277/4885SMN1; SMN2 2306/4885
US-20080058383-A1 Androgen Receptor Modulators NR5A1, ESRRA, AR TDP1 3713/4885TSHR 200/4885SMN1; SMN2 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.